Oncolytics Biotech
ONCY
21 hedge funds and large institutions have $707K invested in Oncolytics Biotech in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
5% more funds holding
Funds holding: 20 → 21 (+1)
2.79% less ownership
Funds ownership: 3.91% → 1.13% (-2.8%)
78% less capital invested
Capital invested by funds: $3.22M → $707K (-$2.51M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$73.4K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$61.8K |
| 3 |
Morgan Stanley
New York
|
+$29.6K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$15.6K |
| 5 |
IP
Intellectus Partners
San Francisco,
California
|
+$9.78K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.06M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$5.11K |
| 3 |
Citigroup
New York
|
-$5K |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
-$4K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.06K |
ONCY Hedge Fund Activity: Q3 2018 in Review
21 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q3 2018, worth a combined $707K — down 78% from $3.22M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ONCY positions and 4 closed out — a net gain of 1 holder — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $73.4K. The largest seller was Millennium Management, cutting an estimated $2.06M.
- 21 institutional investors held Oncolytics Biotech (ONCY) as of Q3 2018, up from 20 in Q2 2018.
- Funds reported $707K of Oncolytics Biotech stock for Q3 2018, down 78% quarter-over-quarter.
- 5 funds opened new Oncolytics Biotech positions in Q3 2018 and 4 closed out, a net change of +1 holder.
- The largest Oncolytics Biotech buyer in Q3 2018 was Renaissance Technologies, an estimated $73.4K added.
- The largest Oncolytics Biotech seller in Q3 2018 was Millennium Management, an estimated $2.06M sold.
Based on aggregated 13F filings for Q3 2018.